Business Wire01.07.19
NAMSA, the world’s only Medical Research Organization (MRO) that accelerates medical device development through integrated laboratory testing, clinical research, and regulatory consulting services, is pleased to announce the acquisition of Reimbursement Strategies, LLC, a Minneapolis-based consultancy focused on reimbursement, health economics, and market access for the international life science industry.
For over 50 years, NAMSA has offered the most critical services required to accelerate time-to-market and reduce costs for global medical device manufacturers. NAMSA, with an established track record of delivering expedited results through the utilization of translational research approaches, will further augment its development services with the addition of in-house reimbursement strategy consulting.
“We are extremely excited about the acquisition of Reimbursement Strategies, LLC, a long-time trusted partner of NAMSA,” commented Christopher Rupp, vice president of global marketing and commercial operations of NAMSA. “The addition of this service will allow clients to proactively address the largest challenges of bringing novel devices to the global marketplace—securing appropriate coverage and payment for new and existing technologies. We look forward to delivering device manufacturers faster, more cost-effective commercialization results through our comprehensive, full-service development solution,” Rupp concluded.
Reimbursement Strategies, LLC, similar to NAMSA, places a significant concentration on providing clients efficacious and timely development outcomes through the organization’s expertise in reimbursement strategy, health economics, medical policy research, and coverage advocacy.
Remarking on the acquisition, former president of Reimbursement Strategies, LLC, Edward Black, stated, “We are very pleased to join the NAMSA Team as we work together to provide clients the most critical services required to navigate our industry’s complicated global reimbursement landscape.” Currently serving as NAMSA’s Director of Global Reimbursement Strategy, Black continued, “It is more important than ever for device manufacturers to assess reimbursement challenges early so they may fully integrate this planning into regulatory and clinical research pathways to achieve resource efficiencies and expedite market commercialization.”
For over 50 years, NAMSA has offered the most critical services required to accelerate time-to-market and reduce costs for global medical device manufacturers. NAMSA, with an established track record of delivering expedited results through the utilization of translational research approaches, will further augment its development services with the addition of in-house reimbursement strategy consulting.
“We are extremely excited about the acquisition of Reimbursement Strategies, LLC, a long-time trusted partner of NAMSA,” commented Christopher Rupp, vice president of global marketing and commercial operations of NAMSA. “The addition of this service will allow clients to proactively address the largest challenges of bringing novel devices to the global marketplace—securing appropriate coverage and payment for new and existing technologies. We look forward to delivering device manufacturers faster, more cost-effective commercialization results through our comprehensive, full-service development solution,” Rupp concluded.
Reimbursement Strategies, LLC, similar to NAMSA, places a significant concentration on providing clients efficacious and timely development outcomes through the organization’s expertise in reimbursement strategy, health economics, medical policy research, and coverage advocacy.
Remarking on the acquisition, former president of Reimbursement Strategies, LLC, Edward Black, stated, “We are very pleased to join the NAMSA Team as we work together to provide clients the most critical services required to navigate our industry’s complicated global reimbursement landscape.” Currently serving as NAMSA’s Director of Global Reimbursement Strategy, Black continued, “It is more important than ever for device manufacturers to assess reimbursement challenges early so they may fully integrate this planning into regulatory and clinical research pathways to achieve resource efficiencies and expedite market commercialization.”
